Exploring the Spectrum of Excessive Daytime Sleepiness

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moderate-to-Severe Asthma Management

Current Management and Future Options for Tardive Dyskinesia

Clinical Trials in IBD.

New Psoriasis Treatments

Psoriatic Arthritis.

Sleep and Myotonic Dystrophy

Improving Survival in Glioblastoma Multiforme

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

Progression After Cancer Immunotherapy in Advanced NSCLC

Reducing Postoperative Ileus

Understanding the Many Faces of Pseudobulbar Affect

Ask the Onychomycosis Expert, Part 2

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Improving Acne Outcomes

Neurostimulation for the Management of Medication-Resistant Epilepsy

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Mid-Year Hemophilia Update

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Beyond the Basics: What You Need to Know About Treating Insomnia

Diagnosis and Management of Narcolepsy in Psychiatry:

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

What Would You Do in This Case of MDD?

Chronic Idiopathic Urticaria

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice

Improving Risk Assessment and Early Diagnosis in PAH

Improving Narcolepsy Diagnosis

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

Multidisciplinary Perspectives on Interstitial Lung Diseases

Nontuberculous Mycobacterial Lung Disease

Improving Outcomes in OSA

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Case Studies in Unresectable Hepatocellular Carcinoma

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Perspectives on the Impact of Inflammation in OA

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Advancing Care Across the Spectrum of Pancreatic Cancer

Traditional Stimulants vs Other Wake-Promoting Agents

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

An Appraisal of Narcolepsy Guidelines

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

HAE Prophylaxis.

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Binge Eating Disorder.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Exploring the Spectrum of Excessive Daytime Sleepiness

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Background

Impact of Sleep Restriction

Defining EDS

Differentiating EDS and Fatigue

Prevalence of EDS

Prevalence of EDS (cont)

Impact of EDS

Case 1

Causes of EDS

Case 1: Differential Diagnosis

Screening Tools for Sleep Disorders

Case 1: Sleep History

Case 1: Evaluation

Case 1: Testing Results

Behavioral Management of EDS in Narcolepsy

FDA-Approved Therapies: Narcolepsy

Emerging Therapies: Narcolepsy

Factors in Initial Treatment Selection for Narcolepsy

Combination Trial: Design

Combination Trial: Results

Case 2

Case 2: History

Case 2: Findings

Case 2: Differential Diagnosis

Case 2: Plan

Case 2: Split-Night Study

Case 2: Return Visit 4 Weeks After Obtaining CPAP

Case 2: PAP-Nap

Case 2: Visit 6 Weeks Later Findings and Diagnosis

EDS Remains After Optimal Treatment of OSA With CPAP

Residual Sleepiness in OSA

Treatment of Residual Sleepiness in OSA

Conclusions

Abbreviations

Abbreviations (cont)